NYSE · Healthcare · Medical - Devices
Glaukos Corporation
GKOS
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. CEO Thomas William Burns · Market cap $10.9B.
$185.62
+1.09 · +0.59%
52w hi $190.0052w lo $73.16
Off 52w high 0.1%
41
ROUTINE
Current InsiderScore
Corp · 90d
2
0 buys · 2 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
0
0 strong · 0 notable
Analyst consensus
Strong Buy
Avg PT $186.00
Section 01
Recent Form 4 filings
4 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Aug 11 | Joseph E Gilliam | PRESIDENT & COO | Sell | 27,963 | $178.89 | −$5.00M | 37 |
| Aug 11 | Joseph E Gilliam | PRESIDENT & COO | Sell | 32,037 | $180.49 | −$5.78M | 41 |
| May 01 | Joseph E Gilliam | PRESIDENT & COO | Sell | 19,573 | $143.54 | −$2.81M | 34 |
| Nov 18 | Joseph E Gilliam | PRESIDENT & COO | Sell | 19,340 | $90.00 | −$1.74M | 34 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
SepOctNovDecJanFebMarAprMayJunJulAug